A Randomized Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma (EA6134)
A Randomized Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma (EA6134)
Trial Category:
Melanoma
Phase
III
Contact(s)
Location(s)
Faith Regional Health System, Carson Cancer Center, Norfolk, NE
Great Plains Health, Callahan Cancer Center, North Platte, NE
Nebraska Cancer Specialists, Omaha, NE
Nebraska Hematology Oncology, Lincoln, NE
Regional West Health Services, Cancer Center, Scottsbluff, NE
Southeast Nebraska Cancer Center, Lincoln, NE
